Xiaoyan Chu

Xiaoyan Chu

Auto-generated profile, based on publicly available information

Xiaoyan Chu

Department of Pharmacokinetics, Dynamics, Metabolism, and Bioanalytics (PDMB), Merck & Co., Inc. Rahway New Jersey USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2012 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
XCXiaoyan Chu
Xiaoyan Chu
KBKelly Bleasby
Kelly Bleasby
RERaymond Evers
Raymond Evers
(2013). Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opinion on Drug Metabolism & Toxicology: Vol. 9, No. 3, pp. 237-252. doi: 10.1517/17425255.2013.741589

10 April 2013 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
XCX Chu
X Chu
AKand Ken Korzekwa
and Ken Korzekwa
RER Elsby
R Elsby
KFK Fenner
K Fenner
AGAleksandra Galetin
Aleksandra Galetin
KBK L R Brouwer
K L R Brouwer

22 October 2018 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
XCXiaoyan Chu
Xiaoyan Chu
MLMingxiang Liao
Mingxiang Liao
HSHong Shen
Hong Shen
KYKenta Yoshida
Kenta Yoshida
AZArik A. Zur
Arik A. Zur
OCon behalf of the International Transporter Consortium
on behalf of the International Transporter Consortium

1 May 2007 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
XCXiao-Yan Chu
Xiao-Yan Chu
KBKelly Bleasby
Kelly Bleasby
JYJocelyn Yabut
Jocelyn Yabut
XCXiaoxin Cai
Xiaoxin Cai
GCGrace Hoyee Chan
Grace Hoyee Chan
RERaymond Evers
Raymond Evers
Sitagliptin, a selective dipeptidyl peptidase 4 inhibitor recently approved for the treatment of type 2 diabetes, is excreted into the urine via active tubular secretion and glomerular filtration in humans. In this report, we demonstrate that sitagliptin is transported by human organic anion transporter hOAT3 (Km = 162 μM), organic anion transporting polypeptide OATP4C1, and multidrug resistance (MDR) P-glycoprotein (Pgp), but not by human organic cation transporter 2 hOCT2, hOAT1, oligopeptide transporter hPEPT1, OATP2B1, and the multidrug resistance proteins MRP2 and MRP4. Our studies suggested that hOAT3, OATP4C1, and MDR1 Pgp might play a role in transporting sitagliptin into and out of renal proximal tubule cells, respectively. Sitagliptin did not inhibit hOAT1-mediated cidofovir uptake, but it showed weak inhibition of hOAT3-mediated cimetidine uptake (IC50 = 160 μM). hOAT3-mediated sitagliptin uptake was inhibited by probenecid, ibuprofen, furosemide, fenofibric acid, quinapril, indapamide, and cimetidine with IC50 values of 5.6, 3.7, 1.7, 2.2, 6.2, 11, and 79 μM, respectively. Sitagliptin did not inhibit Pgp-mediated transport of digoxin, verapamil, ritonavir, quinidine, and vinblastine. Cyclosporine A significantly inhibited Pgp-mediated transport of sitagliptin (IC50 = 1 μM). Our data indicate that sitagliptin is unlikely to be a perpetrator of drug-drug interactions with Pgp, hOAT1, or hOAT3 substrates at clinically relevant concentrations. Renal secretion of sitagliptin could be inhibited if coadministered with OAT3 inhibitors such as probenecid. However, the magnitude of interactions should be low, and the effects may not be clinically meaningful, due to the high safety margin of sitagliptin.

1 May 2006 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
XCXiao-Yan Chu
Xiao-Yan Chu
JSJohn R. Strauss
John R. Strauss
MMMichele A. Mariano
Michele A. Mariano
JLJing Li
Jing Li
DNDeborah J. Newton
Deborah J. Newton
RERaymond Evers
Raymond Evers
The multidrug resistance protein Mrp2 is an ATP-binding cassette (ABC) transporter mainly expressed in liver, kidney, and intestine. One of the physiological roles of Mrp2 is to transport bilirubin glucuronides from the liver into the bile. Current in vivo models to study Mrp2 are the transporter-deficient and Eisai hyperbilirubinemic rat strains. Previous reports showed hyperbilirubinemia and induction of Mrp3 in the hepatocyte sinusoidal membrane in the mutant rats. In addition, differences in liver cytochrome P450 and UGT1a levels between wild-type and mutant rats were detected. To study whether these compensatory mechanisms were specific to rats, we characterized Mrp2–/– mice. Functional absence of Mrp2 in the knockout mice was demonstrated by showing increased levels of bilirubin and bilirubin glucuronides in serum and urine, a reduction in biliary excretion of bilirubin glucuronides and total glutathione, and a reduction in the biliary excretion of the Mrp2 substrate dibromosulfophthalein. To identify possible compensatory mechanisms in Mrp2–/– mice, the expression levels of 98 phase I, phase II, and transporter genes were compared in liver, kidney, and intestine of male and female Mrp2–/– and control mice. Unlike in Mrp2 mutant rats, no induction of Mrp3 in Mrp2–/– mice was detected. However, Mrp4 mRNA and protein in liver and kidney were increased ∼6- and 2-fold, respectively. Phenotypic analysis of major cytochrome P450-mediated activities in liver microsomes did not show differences between wild-type and Mrp2–/– mice. In conclusion, Mrp2–/– mice are a new valuable tool to study the role of Mrp2 in drug disposition.

1 April 2004 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
XCXiao-Yan Chu
Xiao-Yan Chu
SHSu-E. W. Huskey
Su-E. W. Huskey
MBMatthew P. Braun
Matthew P. Braun
BSBalazs Sarkadi
Balazs Sarkadi
DEDavid C. Evans
David C. Evans
RERaymond Evers
Raymond Evers
Ethinylestradiol (EE) is one of the key constituents of oral contraceptives. Major metabolites of EE in humans are the glucuronide and sulfate conjugates, EE-3-O-glucuronide (EE-G) and EE-3-O-sulfate (EE-S). In the present study, transport of EE-G and EE-S by the human multidrug resistance proteins MRP1, MRP2, and MRP3 was investigated using inside-out membrane vesicles, isolated from Sf9 cells expressing human MRP1, MRP2, or MRP3. Vesicular uptake studies showed that EE-G was not a substrate for MRP1, whereas an ATP-dependent and saturable transport of [3H]EE-G was observed in MRP2 (Km of 35.1 ± 3.5 μM) and MRP3 (Km of 9.2 ± 2.3 μM) containing vesicles. EE-S was not transported by either MRP1, MRP2, or MRP3. However, low concentrations of EE-S stimulated MRP2-mediated uptake of ethacrynic acid glutathione. EE-S also stimulated MRP2 and MRP3-mediated uptake of 17β-estradiol-17β-d-glucuronide. Interestingly, EE-S stimulated strongly MRP2- and MRP3-mediated uptake of EE-G by increasing its apparent transport affinity, whereas no reciprocal stimulation of EE-S uptake by EE-G was observed. These data indicate that EE-S allosterically stimulates MRP2- and MRP3-mediated transport of EE-G and is not cotransported with EE-G. Our studies demonstrate specific active transport of a pharmacologically relevant drug conjugate by human MRP2 and MRP3, involving complex interactions with other organic anions. We also suggest that caution needs to be taken when using only competition studies as screening tools to identify substrates or inhibitors of MRP-mediated transport.